HK1200093A1 - Methods of treating melanoma with pak1 inhibitors pak1 - Google Patents

Methods of treating melanoma with pak1 inhibitors pak1

Info

Publication number
HK1200093A1
HK1200093A1 HK15100513.1A HK15100513A HK1200093A1 HK 1200093 A1 HK1200093 A1 HK 1200093A1 HK 15100513 A HK15100513 A HK 15100513A HK 1200093 A1 HK1200093 A1 HK 1200093A1
Authority
HK
Hong Kong
Prior art keywords
pak1
methods
inhibitors
treating melanoma
melanoma
Prior art date
Application number
HK15100513.1A
Other languages
Chinese (zh)
Inventor
Klaus P Hoeflich
Adrian M Jubb
Hartmut Koeppen
Christy C Ong
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1200093A1 publication Critical patent/HK1200093A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15100513.1A 2012-03-16 2015-01-16 Methods of treating melanoma with pak1 inhibitors pak1 HK1200093A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261612202P 2012-03-16 2012-03-16
PCT/EP2013/055085 WO2013135745A1 (en) 2012-03-16 2013-03-13 Methods of treating melanoma with pak1 inhibitors

Publications (1)

Publication Number Publication Date
HK1200093A1 true HK1200093A1 (en) 2015-07-31

Family

ID=47846052

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100513.1A HK1200093A1 (en) 2012-03-16 2015-01-16 Methods of treating melanoma with pak1 inhibitors pak1

Country Status (10)

Country Link
EP (1) EP2844248A1 (en)
JP (1) JP2015511598A (en)
KR (1) KR20140135198A (en)
CN (1) CN104168898A (en)
BR (1) BR112014020173A8 (en)
CA (1) CA2860994A1 (en)
HK (1) HK1200093A1 (en)
MX (1) MX2014010953A (en)
RU (1) RU2014141018A (en)
WO (1) WO2013135745A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016139331A1 (en) * 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
KR101730595B1 (en) 2015-03-18 2017-05-11 충북대학교 산학협력단 Composition for Skin Whitening and Treating Disorders of Melanin Hyperpigmentation Comprising p21-Activated Kinase Inhibitor As Active Ingredient
CN118767143A (en) 2019-12-12 2024-10-15 听治疗有限责任公司 Compositions and methods for preventing and treating hearing loss

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
CH0229046H1 (en) 1985-03-30 1998-07-15 Stuart Alan Kauffman METHOD FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTINIQUE. DES OR PROTEINS BY MEANS OF A DNA RECOMBINANT TECH
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0760012A4 (en) 1994-06-10 1997-07-02 Symbiotech Inc Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
WO1997009446A1 (en) 1995-09-07 1997-03-13 Novo Nordisk A/S Phage display for detergent enzyme activity
DE69731084T2 (en) 1996-03-20 2006-02-23 Dyax Corp., Cambridge CLEANING OF TISSUE PLASMINOGENACTIVATOR (tPA)
WO1997046251A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE69731226T2 (en) 1996-06-10 2006-03-09 The Scripps Research Institute, La Jolla USE OF SUBSTRATE SUBTRACTION LIBRARIES FOR THE DISTINCTION OF ENZYME SPECIFICATIONS
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
WO1998014277A1 (en) 1996-10-04 1998-04-09 Whatman, Inc. Device and method for simultaneous multiple chemical syntheses
JP2001512560A (en) 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ Methods and means for the selection of peptides and proteins with specific affinity for a target
EP0938497B1 (en) 1996-11-06 2007-02-28 Genentech, Inc. Constrained helical peptides and methods of making same
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1141708A1 (en) 1998-12-28 2001-10-10 Sunesis Pharmaceuticals Inc. Identifying small organic molecule ligands for binding
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
CA2492673A1 (en) 2002-07-17 2004-01-22 Pharmacia Italia S.P.A. Heterobicyclic pyrazole derivatives as kinase inhibitors
SI1838718T1 (en) * 2005-01-10 2011-08-31 Pfizer Pyrrolopyrazoles, potent kinase inhibitors
KR20080009200A (en) 2005-04-06 2008-01-25 아스트라제네카 아베 Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
MEP0808A (en) 2005-12-21 2010-02-10 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
US20100317715A1 (en) 2007-12-21 2010-12-16 Vollrath Benedikt Methods for treating neuropsychiatric conditions
ES2306630B1 (en) 2008-07-17 2009-06-03 Encarnacion Mira Rodriguez ANTIFLACIDEZ AND ANTIWRINK DEVICE.
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
WO2011044264A2 (en) 2009-10-06 2011-04-14 Afraxis, Inc. Pyrrolopyrazoles for treating cns disorders
KR20120104200A (en) 2009-10-09 2012-09-20 아프락시스 인코포레이티드 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US20130231348A1 (en) 2010-06-09 2013-09-05 Afraxis, Inc. 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS
EP2580214A4 (en) 2010-06-09 2013-12-04 Afraxis Holdings Inc 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
WO2011156775A2 (en) 2010-06-10 2011-12-15 Afraxis, Inc. 8-(2'-heterocycyl)pyrido[2.3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
US8680099B2 (en) 2010-06-10 2014-03-25 Afraxis Holdings, Inc. 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
EP2580216A4 (en) 2010-06-10 2014-07-23 Afraxis Holdings Inc 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders

Also Published As

Publication number Publication date
KR20140135198A (en) 2014-11-25
CA2860994A1 (en) 2013-09-19
BR112014020173A8 (en) 2017-07-11
JP2015511598A (en) 2015-04-20
CN104168898A (en) 2014-11-26
EP2844248A1 (en) 2015-03-11
WO2013135745A1 (en) 2013-09-19
MX2014010953A (en) 2014-10-13
BR112014020173A2 (en) 2017-06-20
RU2014141018A (en) 2016-05-10

Similar Documents

Publication Publication Date Title
HK1218506A1 (en) Methods of treating melanoma
HK1213889A1 (en) Glutaminase inhibitors and method of use
HK1206736A1 (en) Seca inhibitors and methods of making and using thereof seca
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
PL3447052T3 (en) Methods of preparing new idh1 inhibitors
AP4029A (en) Inhibitors of beta-secretase
PL2909204T3 (en) Gsk3 inhibitors and methods of use thereof
HK1202112A1 (en) Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
IL260115A (en) Methods of treating fibrosis
IL236138A0 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
HRP20181000T1 (en) Methods of treating hair related conditions
IL236963A0 (en) Inhibitors of beta-secretase
HK1201066A1 (en) Pyranopyridone inhibitors of tankyrase
EP2688901A4 (en) INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
HK1200093A1 (en) Methods of treating melanoma with pak1 inhibitors pak1
PT2811993T (en) Methods of treating fibrosis